Our study found that HER2 amplification altered the transcriptomic profiles in DCIS, and particularly, interferon signaling pathway was activated by HER2 amplification in DCIS, which may provide a prolonged interferon signaling activation in HER2-positive breast cancer. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.